The publication of the SIERRA trial results in the Journal of Clinical Oncology is a significant milestone for Iomab-B. The trial demonstrated statistically significant improvements in durable Complete Remission (22% vs 0%, p&LT0.0001) and Event-Free Survival in relapsed/refractory AML patients. This is particularly noteworthy given the challenging nature of this patient population, including those with TP53 mutations. However, the FDA's requirement for an additional trial to demonstrate overall survival benefit is a setback. This decision likely stems from the high crossover rate (60%) in the control arm, which complicated the overall survival analysis. The need for a new trial will significantly delay potential market entry and increase development costs, impacting Actinium's near-term prospects.